Compare Citius Pharmaceuticals Inc (CTXR) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs GE Aerospace — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while GE Aerospace trades at $368.48 (market cap $380.47B). The key difference: GE Aerospace is far larger — about 20313.4× Citius Pharmaceuticals Inc's market cap, and GE Aerospace pays a 0.51% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GE | |
|---|---|---|
Market Cap | $18.73M | $380.47B |
Sector | Health | Industrials |
52-Week High | $1.82 | $381.22 |
52-Week Low | $0.48 | $265.93 |
Enterprise Value | $14.95M | $390.29B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
GE Aerospace (GE) trades at $368.06, down 0.55% with a bullish technical signal supported by strong earnings beats and robust order growth. The company shows impressive profitability with 48.79% ROE and 17.72% net margin, though valuation metrics appear elevated with a P/E of 43.24. Recent defense contract wins and commercial engine demand fuel positive sentiment, with analysts maintaining strong buy consensus.
GE presents growth potential through aerospace expansion and defense contracts, but faces risks from high debt levels and rich valuations. The $414.11 price target suggests 12.5% upside, supported by consistent earnings outperformance and strategic investments in manufacturing capacity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
